A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations

Clin Neuropharmacol. 1989 Feb;12(1):37-45. doi: 10.1097/00002826-198902000-00005.

Abstract

We describe a simple quantitative bedside method for assessing the dopaminergic properties of new therapeutic agents, namely, by documenting their duration of action in patients with Parkinson's disease who exhibit "on-off" fluctuations. This model represents a form of human dopaminergic "bioassay".

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / pharmacology*
  • Dopamine Agents / pharmacology*
  • Drug Evaluation / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Oxazines / pharmacology*
  • Parkinson Disease / drug therapy*

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Oxazines
  • naxagolide